EE05006B1 - Polü(ADP-riboos)polümeraaside tritsüklilised inhibiitorid ja neid sisaldavad farmatseutilised kompositsioonid - Google Patents

Polü(ADP-riboos)polümeraaside tritsüklilised inhibiitorid ja neid sisaldavad farmatseutilised kompositsioonid

Info

Publication number
EE05006B1
EE05006B1 EEP200100364A EEP200100364A EE05006B1 EE 05006 B1 EE05006 B1 EE 05006B1 EE P200100364 A EEP200100364 A EE P200100364A EE P200100364 A EEP200100364 A EE P200100364A EE 05006 B1 EE05006 B1 EE 05006B1
Authority
EE
Estonia
Prior art keywords
polymerases
adp
ribose
poly
pharmaceutical compositions
Prior art date
Application number
EEP200100364A
Other languages
English (en)
Inventor
Evan Webber Stephen
S. Canan-Koch Stacie
Girish Tikhe Jayashree
Henrik Thoresen Lars
Original Assignee
Agouron Pharmaceuticals, Inc.
Cancer Research Campaign Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals, Inc., Cancer Research Campaign Technology Limited filed Critical Agouron Pharmaceuticals, Inc.
Publication of EE200100364A publication Critical patent/EE200100364A/et
Publication of EE05006B1 publication Critical patent/EE05006B1/et

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EEP200100364A 1999-01-11 2000-01-10 Polü(ADP-riboos)polümeraaside tritsüklilised inhibiitorid ja neid sisaldavad farmatseutilised kompositsioonid EE05006B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11543199P 1999-01-11 1999-01-11
PCT/US2000/000411 WO2000042040A1 (en) 1999-01-11 2000-01-10 Tricyclic inhibitors of poly(adp-ribose) polymerases

Publications (2)

Publication Number Publication Date
EE200100364A EE200100364A (et) 2002-10-15
EE05006B1 true EE05006B1 (et) 2008-04-15

Family

ID=22361361

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100364A EE05006B1 (et) 1999-01-11 2000-01-10 Polü(ADP-riboos)polümeraaside tritsüklilised inhibiitorid ja neid sisaldavad farmatseutilised kompositsioonid

Country Status (40)

Country Link
US (4) US6495541B1 (et)
EP (1) EP1140936B1 (et)
JP (1) JP4093448B2 (et)
KR (1) KR100632079B1 (et)
CN (1) CN100418967C (et)
AP (1) AP1538A (et)
AT (1) ATE261963T1 (et)
AU (1) AU781711B2 (et)
BG (1) BG65210B1 (et)
BR (1) BRPI0008614B8 (et)
CA (1) CA2360003C (et)
CZ (1) CZ302941B6 (et)
DE (1) DE60009033T2 (et)
DK (1) DK1140936T3 (et)
EA (1) EA004989B1 (et)
EE (1) EE05006B1 (et)
ES (1) ES2218110T3 (et)
GE (1) GEP20033055B (et)
HK (1) HK1040992A1 (et)
HR (1) HRP20010573B1 (et)
HU (1) HU229875B1 (et)
ID (1) ID30138A (et)
IL (2) IL144112A0 (et)
IS (1) IS5995A (et)
LT (1) LT4936B (et)
LV (1) LV12770B (et)
MX (1) MXPA01007001A (et)
NO (1) NO320343B1 (et)
NZ (1) NZ512731A (et)
OA (2) OA11749A (et)
PL (1) PL210415B1 (et)
PT (1) PT1140936E (et)
RO (1) RO121778B1 (et)
RS (1) RS50031B (et)
SI (1) SI20691B (et)
SK (1) SK287338B6 (et)
TR (1) TR200102005T2 (et)
UA (1) UA75034C2 (et)
WO (1) WO2000042040A1 (et)
ZA (1) ZA200105399B (et)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2352194A1 (en) * 1999-09-28 2001-04-05 Basf Aktiengesellschaft Azepinoindole derivatives, the production and use thereof
US6589725B1 (en) 1999-10-25 2003-07-08 Rigel Pharmaceuticals, Inc. Tankyrase H, compositions involved in the cell cycle and methods of use
US6476048B1 (en) 1999-12-07 2002-11-05 Inotek Pharamaceuticals Corporation Substituted phenanthridinones and methods of use thereof
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
BR0109430A (pt) * 2000-03-20 2002-12-10 N Gene Res Lab Inc Derivados amidoxima de ácido propenocarboxìlico, processo para a preparação dos mesmos, e composições farmacêuticas que contêm os mesmos
US6534651B2 (en) 2000-04-06 2003-03-18 Inotek Pharmaceuticals Corp. 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof
WO2002044183A2 (en) 2000-12-01 2002-06-06 Guilford Pharmaceuticals Inc. Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
US6664269B2 (en) 2001-05-08 2003-12-16 Maybridge Plc Isoquinolinone derivatives
US6924284B2 (en) 2001-08-15 2005-08-02 Icos Corporation PARP inhibitors
US6956035B2 (en) 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
US20030096833A1 (en) 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof
WO2003051879A1 (en) * 2001-12-14 2003-06-26 Altana Pharma Ag Known and novel 4,5-dihydro-imidazo[4,5,1-ij]quinolin-6-ones useful as poly(adp-ribose)polymerase inhibitors
WO2003093261A1 (en) 2002-04-30 2003-11-13 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2004063198A1 (en) * 2003-01-09 2004-07-29 Pfizer Inc. Diazepinoindole derivatives as kinase inhibitors
US7217709B2 (en) 2003-02-28 2007-05-15 Inotek Pharmaceuticals Corporation Tetracyclic benzamide derivatives and methods of use thereof
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
JP2006522088A (ja) * 2003-03-31 2006-09-28 ファイザー・インク ポリ(adp−リボース)ポリメラーゼの三環系阻害剤の塩
ES2396334T3 (es) * 2003-05-28 2013-02-20 Eisai Inc. Compuestos, métodos y composiciones farmacéuticas para la inhibición de PARP
GB0317466D0 (en) * 2003-07-25 2003-08-27 Univ Sheffield Use
PT1660095E (pt) 2003-07-25 2010-04-19 Pfizer Inibidores tricíclicos de parp
KR20060123403A (ko) 2003-12-01 2006-12-01 쿠도스 파마슈티칼스 리미티드 암 치료를 위한 dna 손상 수복 억제제
US20050228007A1 (en) 2004-02-26 2005-10-13 Prakash Jagtap Isoquinoline derivatives and methods of use thereof
WO2006033003A1 (en) 2004-09-22 2006-03-30 Pfizer, Inc. Method of preparing poly(adp-ribose) polymerases inhibitors
KR20070046183A (ko) * 2004-09-22 2007-05-02 화이자 인코포레이티드 폴리(에이디피-리보오스) 폴리머라제 저해제를 포함하는치료 배합물
CN101133061B (zh) * 2004-09-22 2011-09-07 辉瑞有限公司 8-氟-2-{4-[(甲基氨基)甲基]苯基}-1,3,4,5-四氢-6H-氮杂卓并[5,4,3-cd]吲哚-6-酮的磷酸盐的多晶型物和非晶物
BRPI0516766A (pt) * 2004-09-22 2008-09-16 Pfizer formas polimórficas e amorfas do sal de fosfato de 8-flúor-2{4-[(metilamino)metil]fenil}-1,3,4,5-tetraidro- 6h-azepino[5,4,3-cd]indol-6-ona, composição farmacêutica, formas de dosagens e respectivo uso
MX2007008771A (es) 2005-01-19 2007-09-11 Mgi Gp Inc Compuestos de diazabenzo [des] antracen-3-ona y metodos para inhibir parp.
US7381722B2 (en) 2005-02-25 2008-06-03 Inotek Pharmaceuticals Corporation Tetracyclic amino and carboxamido compounds and methods of use thereof
US7297700B2 (en) 2005-03-24 2007-11-20 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
DE102005022111A1 (de) * 2005-05-12 2006-11-16 Siemens Ag Verfahren zum Datenaustausch
EP1908481A1 (en) * 2005-06-24 2008-04-09 Ono Pharmaceutical Co., Ltd. Agent for reduction of bleeding in cerebrovascular disorder
CA2612442A1 (en) 2005-07-14 2007-01-18 Irm Llc Heterotetracyclic compounds as tpo mimetics
JP5177429B2 (ja) 2005-07-18 2013-04-03 バイパー サイエンシズ,インコーポレイティド 癌の治療
CN101316592A (zh) 2005-08-24 2008-12-03 伊诺泰克制药公司 茚并异喹啉酮类似物及其用法
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
CN101370497B (zh) * 2006-01-17 2010-11-17 雅培制药有限公司 包含parp抑制剂和细胞毒性剂的联合产品及用途
TWI464148B (zh) 2006-03-16 2014-12-11 Evotec Us Inc 作為p2x7調節劑之雙環雜芳基化合物與其用途
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
WO2008030883A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
WO2008030891A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
MX2009009183A (es) 2007-02-28 2009-09-07 Inotek Pharmaceuticals Corp Analogos de indenoisoquinolinona y metodos de utilizacion de los mismos.
WO2008154129A1 (en) * 2007-06-08 2008-12-18 Bausch & Lomb Incorporated Pharmaceutical compositions and method for treating, reducing, ameliorating, alleviating, or preventing dry eye
BRPI0816679A2 (pt) 2007-09-14 2015-03-17 Astrazeneca Ab Derivados de ftalazinona.
MX2010003564A (es) 2007-10-03 2010-09-10 Eisai Inc Compuestos inhibidores de poli(adenosina-5'-difosfo-ribosa)polimer asa (parp), composiciones y metodos de uso.
NZ586125A (en) 2007-11-12 2012-12-21 Bipar Sciences Inc Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
HUE030800T2 (en) 2008-10-07 2017-05-29 Astrazeneca Uk Ltd Pharmaceutical Form No. 514
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
KR100986820B1 (ko) * 2010-01-27 2010-10-12 (주)에코베이스 막힘방지형 고효율 산기장치 및 이를 이용한 수질정화장치
EP4166558A1 (en) 2010-02-12 2023-04-19 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
JP5699223B2 (ja) 2010-12-02 2015-04-08 シャンハイ デュァ ノボ ファルマテック カンパニー リミテッド 複素環誘導体、その合成法および医療用途
AU2011384859B2 (en) 2011-12-31 2016-03-17 Beigene, Ltd. Fused tetra or penta-cyclic pyridophthalazinones as PARP inhibitors
ME02855B (me) 2011-12-31 2018-04-20 Beigene Ltd KONDENZOVANI TETRA ILl PENTA-CIKLIČNI DIHIDRODIAZEPINOKARBAZOLONI KAO PARP INHIBITORI
US9855261B2 (en) 2012-11-08 2018-01-02 Nippon Kayaku Kabushiki Kaisha Polymeric compound having camptothecin compound and anti-cancer effect enhancer bound thereto, and use of same
WO2015103526A1 (en) 2014-01-05 2015-07-09 Washington University Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor
CN103772395B (zh) * 2014-01-23 2016-05-11 中国药科大学 一类具有parp抑制活性的化合物、其制备方法及用途
SG10201811175WA (en) 2014-06-17 2019-01-30 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
AU2015305696B2 (en) 2014-08-22 2019-08-29 Pharma& Schweiz Gmbh High dosage strength tablets of rucaparib
CN105607772B (zh) * 2014-11-13 2020-11-03 现代自动车株式会社 触摸输入装置以及包括该装置的车辆
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
US11261466B2 (en) 2015-03-02 2022-03-01 Sinai Health System Homologous recombination factors
DK3325623T6 (da) 2015-07-23 2021-03-15 Inst Curie Anvendelse af en kombination af dbait-molekyle og parp-inhibitorer til behandling af kræft
NZ739876A (en) 2015-08-25 2022-09-30 Beigene Ltd Process for preparing parp inhibitor, crystalline forms, and uses thereof
EP3355926A4 (en) 2015-09-30 2019-08-21 Vertex Pharmaceuticals Inc. METHOD FOR THE TREATMENT OF CANCER WITH A COMBINATION OF DNA DAMAGING AGENTS AND ATR INHIBITORS
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
CN107286166B (zh) * 2016-04-11 2020-03-31 上海勋和医药科技有限公司 取代1,3,4,5-四氢-6h-吡咯并[4,3,2-ef][2]苯并氮杂-6-酮衍生物
WO2018022851A1 (en) 2016-07-28 2018-02-01 Mitobridge, Inc. Methods of treating acute kidney injury
EP3519051B1 (en) 2016-09-27 2021-09-22 Beigene, Ltd. Treatment of cancers using combination comprising parp inhibitors
JP6541635B2 (ja) * 2016-10-28 2019-07-10 ベイジーン リミテッド Parp阻害剤としての縮合四環式または縮合五環式ジヒドロジアゼピノカルバゾロン
CA3041843A1 (en) 2016-11-02 2018-05-11 Immunogen, Inc. Combination treatment with antibody-drug conjugates and parp inhibitors
CN106854172B (zh) * 2016-12-11 2019-04-19 山东轩德医药科技有限公司 一种6-氟-1h-吲哚-4-甲酸甲酯的制备方法
WO2018122168A1 (en) 2016-12-29 2018-07-05 Bayer Pharma Aktiengesellschaft Combinations of bub1 kinase and parp inhibitors
US10875870B2 (en) * 2017-01-24 2020-12-29 Assia Chemical Industries Ltd. Solid state forms of rucaparib and of rucaparib salts
CN106748958B (zh) * 2017-01-25 2018-12-18 伦俊杰 一种Rucaparib中间体的制备方法
CN115433187B (zh) 2017-02-28 2023-10-27 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式组合物及其用途
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
CN110997068B (zh) * 2017-05-24 2022-12-06 宾夕法尼亚大学董事会 用于成像和放射疗法的经放射标记的荧光parp抑制剂
IT201700085789A1 (it) 2017-07-26 2019-01-26 Olon Spa Metodo per la preparazione di rucaparib ad elevata purezza
AU2018306726B2 (en) * 2017-07-28 2023-08-03 Yale University Anticancer drugs and methods of making and using same
CN109651376B (zh) * 2017-10-12 2022-06-03 江苏创诺制药有限公司 一种氮杂卓并[5,4,3-cd]吲哚-6-酮化合物的合成方法
CN109651377B (zh) * 2017-10-12 2020-10-20 成都海创药业有限公司 一种治疗癌症的化合物及其用途
CA3080657A1 (en) * 2017-11-03 2019-05-09 Sandoz Ag Crystalline salt of a tricyclic poly(adp-ribose) polymerase inhibitor
US11220507B2 (en) 2017-12-15 2022-01-11 Advitech Advisory And Technologies Sa Process for the preparation of rucaparib and novel synthesis intermediates
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
WO2019136298A1 (en) * 2018-01-05 2019-07-11 Cybrexa, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
US10442813B2 (en) 2018-01-30 2019-10-15 RK Pharma Solutions LLC Polymorphs of rucaparib camsylate and methods of making same
CN110229162B (zh) * 2018-03-05 2020-08-11 新发药业有限公司 一种瑞卡帕布的简便制备方法
KR20200130856A (ko) 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
CN110272419A (zh) * 2018-03-14 2019-09-24 上海艾力斯医药科技有限公司 二氢吡啶并酞嗪酮衍生物、其制备方法及应用
WO2019207596A1 (en) 2018-04-25 2019-10-31 Mylan Laboratories Limited Novel crystalline forms of rucaparib (s)-camsylate salt and rucaparib free base
CN108743557A (zh) * 2018-06-27 2018-11-06 李莉 一种磷酸瑞卡帕布软胶囊及其制备方法
CN108976236B (zh) * 2018-08-16 2020-11-10 湖南华腾制药有限公司 一种氘代parp抑制剂、其盐、其制备方法及用途
CN111217818A (zh) * 2018-11-27 2020-06-02 台耀化学股份有限公司 芦卡帕尼樟脑磺酸盐的结晶、及制备三环化合物、芦卡帕尼及其樟脑磺酸盐结晶的方法
BR112021015149A2 (pt) * 2019-02-02 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co., Ltd Análogo de indolo heptamil oxima como inibidor de parp
WO2020229595A1 (en) 2019-05-14 2020-11-19 Molecular Targeted Radiopharmaceuticals Holding Gmbh (Mtr) Quinazoline-2,4-dione derivatives as parp inhibitors
CN110256468B (zh) * 2019-05-14 2020-09-01 山东省分析测试中心 双吲哚生物碱化合物或其药学上可接受的盐及其制备方法和应用
TW202116778A (zh) 2019-07-10 2021-05-01 美商斯布雷克薩二號公司 作為治療劑之細胞毒素之肽結合物
KR20220051332A (ko) 2019-07-10 2022-04-26 싸이브렉사 3, 인크. 치료제로서의 미세소관 표적화제의 펩티드 접합체
WO2021018298A1 (zh) * 2019-08-01 2021-02-04 南京明德新药研发有限公司 作为parp抑制剂吲哚并七元酰肟化合物
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021156140A1 (en) 2020-02-03 2021-08-12 Sandoz Ag Polymorph of rucaparib mesylate
WO2021169984A1 (zh) 2020-02-24 2021-09-02 甫康(上海)健康科技有限责任公司 聚adp核糖聚合酶抑制剂在抗冠状病毒中的应用
EP4143182A1 (en) 2020-04-28 2023-03-08 Rhizen Pharmaceuticals AG Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
CN111646990B (zh) * 2020-05-22 2023-01-10 同济大学 一种3,4-桥环吲哚类化合物的制备方法及Rucaparib的合成方法
CN111662299B (zh) * 2020-07-10 2022-07-26 中山大学 一种取代吲哚并氮杂酮类化合物及其制备方法和应用
EP4182318A1 (en) 2020-07-14 2023-05-24 Assia Chemical Industries Ltd Solid state forms of rucaparib salts
WO2022022664A1 (zh) * 2020-07-31 2022-02-03 正大天晴药业集团股份有限公司 用作parp抑制剂的吲哚并七元酰肟类似物的结晶及其制备方法
CN111961047A (zh) * 2020-08-19 2020-11-20 南通大学 一种6-乙氧基-3,4-二氢-2,7-萘啶-1(2h)-酮及其合成方法
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
EP4274905A1 (en) 2021-01-08 2023-11-15 Cybrexa 2, Inc. Process for preparing a conjugate linking moiety
WO2022155172A1 (en) 2021-01-13 2022-07-21 Cybrexa 3, Inc. Peptide conjugates of therapeutics
AU2022255809A1 (en) 2021-04-08 2023-10-26 Incozen Therapeutics Pvt. Ltd. Inhibitors of poly(adp-ribose) polymerase
KR20230157374A (ko) * 2021-05-18 2023-11-16 온코닉 테라퓨틱스 주식회사 트리사이클릭 유도체 화합물의 결정형 및 이의 제조방법및 이를 포함하는 약학적 조성물
WO2023137060A1 (en) 2022-01-11 2023-07-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate
WO2023201338A1 (en) 2022-04-15 2023-10-19 Ideaya Biosciences, Inc. Combination therapy comprising a mat2a inhibitor and a parp inhibitor
WO2023233295A1 (en) 2022-06-01 2023-12-07 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642820A (en) 1969-11-03 1972-02-15 Upjohn Co 4 5-dihydropyrrolo(3 2 1-jk)(1 4)bezodiazepines
US3883590A (en) 1971-06-01 1975-05-13 Universal Oil Prod Co Preparation of n-alkylarylcarboxamides
DE2322434A1 (de) 1973-05-04 1974-11-21 Bayer Ag 2-trifluormethylimino-1,3-dithioloeckige klammer auf 4,5-b eckige klammer zu -chinoxaline, verfahren zu ihrer herstellung, sowie ihre verwendung als insektizide, akarizide und fungizide
US4033960A (en) 1973-07-31 1977-07-05 Bayer Aktiengesellschaft 2-Mercaptoquinoxaline-di-N-oxide products and a method for their preparation
US3900477A (en) 1973-11-06 1975-08-19 Ayerst Mckenna & Harrison 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives
US3978066A (en) 1973-11-06 1976-08-31 Ayerst, Mckenna And Harrison Ltd. Certain 4,6-dihydropyrrolotriazoline-quinoline derivatives
US3950343A (en) 1973-11-06 1976-04-13 Ayerst, Mckenna And Harrison Ltd. Pyrroloisoquinoline derivatives
US3959343A (en) * 1974-10-25 1976-05-25 Wako Pure Chemical Industries, Ltd. Process for producing hydrazonitriles
DE2913728A1 (de) 1979-04-05 1980-10-16 Bayer Ag 2-sulfonyl-chinoxaline, verfahren zu ihrer herstellung sowie ihre verwendung als mikrobizide
DE3103137A1 (de) 1981-01-30 1982-08-26 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung aliphatischer cyclischer kohlensaeureester
JPS57144286A (en) 1981-03-02 1982-09-06 Takeda Chem Ind Ltd Azepinoindole derivative and its preparation
US5215738A (en) 1985-05-03 1993-06-01 Sri International Benzamide and nicotinamide radiosensitizers
US4910193A (en) 1985-12-16 1990-03-20 Sandoz Ltd. Treatment of gastrointestinal disorders
JPS6434988A (en) * 1987-07-30 1989-02-06 Kissei Pharmaceutical Azepinoindole derivative
DE4125292A1 (de) * 1991-07-31 1993-02-04 Kali Chemie Pharma Gmbh 6-oxo-azepinoindol-verbindungen sowie verfahren und zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9117987D0 (en) 1991-08-20 1991-10-09 Ici Plc Heterocyclic compounds
US5342946A (en) 1992-12-02 1994-08-30 Guilford Pharmaceuticals Inc. Phosphonoalkylquinolin-2-ones as novel antagonists of non-NMDA ionotropic excitatory amino acid receptors
CN1114834A (zh) 1993-09-28 1996-01-10 大塚制药株式会社 抗糖尿病剂
US5587384A (en) 1994-02-04 1996-12-24 The Johns Hopkins University Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity
GB9404485D0 (en) 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
US5561161A (en) 1994-03-25 1996-10-01 Oxigene, Inc. Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
US5589483A (en) 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
ES2105959B1 (es) 1995-01-17 1998-07-01 Zeneca Pharma Sa Derivados de 1,4-dioxido de quinoxalina, procedimiento de preparacion y de utilizacion.
US5756548A (en) 1995-04-03 1998-05-26 Centaur Pharmaceuticals, Inc. Acetamidobenzamide compounds for neurodegenerative disorders
US5659082A (en) 1995-04-03 1997-08-19 Centaur Pharmaceuticals, Inc. Nitro- and aminobenzamide compounds for neurodegenerative disorders
DE69624115T2 (de) 1995-08-02 2003-06-18 Univ Newcastle Ventures Ltd Benzimidazol verbindungen
HUT76302A (en) 1995-11-30 1997-07-28 Chinoin Gyogyszer Es Vegyeszet Quinoxaline derivatives, pharmaceutical compositions containing them and process for producing them
US6028111A (en) 1996-03-08 2000-02-22 Oxigene, Inc. Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
GB9702701D0 (en) 1997-02-01 1997-04-02 Univ Newcastle Ventures Ltd Quinazolinone compounds
AU745790B2 (en) 1997-05-13 2002-03-28 Octamer, Inc. Methods for treating inflammation and inflammatory diseases using pADPRT inhibitors
US20020022636A1 (en) 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US20020028813A1 (en) 1997-09-03 2002-03-07 Paul F. Jackson Thioalkyl compounds, methods, and compositions for inhibiting parp activity
US6514983B1 (en) 1997-09-03 2003-02-04 Guilford Pharmaceuticals Inc. Compounds, methods and pharmaceutical compositions for treating neural or cardiovascular tissue damage
US6197785B1 (en) 1997-09-03 2001-03-06 Guilford Pharmaceuticals Inc. Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity
AU9298198A (en) 1997-09-03 1999-03-22 Guilford Pharmaceuticals Inc. Di-n-heterocyclic compounds, methods, and compositions for inhibiting parp activity
WO1999011622A1 (en) 1997-09-03 1999-03-11 Guilford Pharmaceuticals Inc. Amino-substituted compounds, methods, and compositions for inhibiting parp activity
US6635642B1 (en) 1997-09-03 2003-10-21 Guilford Pharmaceuticals Inc. PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same
EP1077944A1 (en) 1998-05-15 2001-02-28 Guilford Pharmaceuticals Inc. Carboxamide compounds, compositions, and methods for inhibiting parp activity
WO1999059975A1 (en) * 1998-05-15 1999-11-25 Guilford Pharmaceuticals Inc. Fused tricyclic compounds which inhibit parp activity
DE19946289A1 (de) 1999-09-28 2001-03-29 Basf Ag Benzodiazepin-Derivate, deren Herstellung und Anwendung
CA2352194A1 (en) 1999-09-28 2001-04-05 Basf Aktiengesellschaft Azepinoindole derivatives, the production and use thereof

Also Published As

Publication number Publication date
EP1140936B1 (en) 2004-03-17
PT1140936E (pt) 2004-06-30
CN100418967C (zh) 2008-09-17
CA2360003A1 (en) 2000-07-20
ATE261963T1 (de) 2004-04-15
US20030078254A1 (en) 2003-04-24
EP1140936A1 (en) 2001-10-10
PL357049A1 (en) 2004-07-12
NZ512731A (en) 2004-01-30
DE60009033T2 (de) 2004-08-05
BG65210B1 (bg) 2007-07-31
GEP20033055B (en) 2003-08-25
IS5995A (is) 2001-07-10
HU229875B1 (en) 2014-11-28
AP1538A (en) 2006-01-10
EE200100364A (et) 2002-10-15
KR20020008112A (ko) 2002-01-29
HUP0105414A3 (en) 2003-04-28
HK1040992A1 (en) 2002-06-28
AU2408800A (en) 2000-08-01
RS50031B (sr) 2008-11-28
NO20013313D0 (no) 2001-07-04
NO320343B1 (no) 2005-11-28
US20050085460A1 (en) 2005-04-21
SI20691A (sl) 2002-04-30
US6977298B2 (en) 2005-12-20
LT4936B (lt) 2002-07-25
YU49001A (sh) 2005-11-28
UA75034C2 (en) 2006-03-15
US6495541B1 (en) 2002-12-17
OA11749A (en) 2005-07-19
CN1342161A (zh) 2002-03-27
PL210415B1 (pl) 2012-01-31
SK287338B6 (sk) 2010-07-07
HRP20010573B1 (en) 2006-04-30
HUP0105414A2 (hu) 2002-05-29
CZ20012443A3 (cs) 2002-02-13
OA12185A (en) 2006-05-09
DE60009033D1 (de) 2004-04-22
BR0008614A (pt) 2001-10-16
TR200102005T2 (tr) 2001-12-21
HRP20010573A2 (en) 2005-02-28
JP4093448B2 (ja) 2008-06-04
BG105811A (en) 2002-05-31
NO20013313L (no) 2001-09-10
LV12770A (en) 2001-12-20
LT2001083A (en) 2002-03-25
MXPA01007001A (es) 2002-07-30
DK1140936T3 (da) 2004-06-21
WO2000042040A1 (en) 2000-07-20
AU781711B2 (en) 2005-06-09
JP2002534523A (ja) 2002-10-15
US7429578B2 (en) 2008-09-30
SK9662001A3 (en) 2002-04-04
EA200100764A1 (ru) 2002-06-27
IL144112A (en) 2006-07-05
IL144112A0 (en) 2002-05-23
KR100632079B1 (ko) 2006-10-04
RO121778B1 (ro) 2008-04-30
CZ302941B6 (cs) 2012-01-25
ZA200105399B (en) 2002-07-01
ES2218110T3 (es) 2004-11-16
BR0008614B1 (pt) 2014-11-25
CA2360003C (en) 2012-07-10
LV12770B (lv) 2002-05-20
AP2001002211A0 (en) 2001-09-30
BRPI0008614B8 (pt) 2021-05-25
ID30138A (id) 2001-11-08
SI20691B (sl) 2008-10-31
EA004989B1 (ru) 2004-10-28
US20060009517A1 (en) 2006-01-12

Similar Documents

Publication Publication Date Title
EE05006B1 (et) Polü(ADP-riboos)polümeraaside tritsüklilised inhibiitorid ja neid sisaldavad farmatseutilised kompositsioonid
HUP0202703A3 (en) Tricyclic inhibitors of poly(adp-ribose) polymerases and pharmaceutical compositions containing them and their use
EE200200149A (et) Kinasoliinühendid ja neid sisaldavad ravimkoostised
NO20011950D0 (no) Farmasöytisk sammensetning inneholdende poly(ADP- ribose)glykohydrolaseinhibitorer og anvendelser av de samme
EE200100484A (et) Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid,ja nende valmistamise meetodid
EE04799B1 (et) Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid
EE04853B1 (et) Adenosiini derivaadid ja neid sisaldavad farmatseutilised kompositsioonid kasutamiseks meditsiinis
PT813873E (pt) Composicao farmaceutica compreendendo mirtazapina e um ou mais inibidores selectivos da recaptacao de serotonina
EE200200138A (et) Kinolüülpropüülpiperidiini derivaadid, nende valmistamine ja neid sisaldavad kompositsioonid
EE200000168A (et) Karboksamidotiasoolderivaadid, nende valmistamine ja neid sisaldavad farmatseutilised kompositsioonid
EE200100529A (et) Diabeedivastase agensi uudsed polümorfsed vormid:nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
NO20004311D0 (no) Farmasøytisk sammensetning av topiramat
NO20024386D0 (no) Farmasöytiske sammensetninger av glycogenfosforylase- inhibitorer
EE04015B1 (et) Asendatud 2,4-tiasolidiindiooni derivaadid, nendevalmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid
HUP0102714A3 (en) Tricyclic sulfonamid derivatives as inhibitors of matrix metalloproteinases and medicaments containing the same
EE9900426A (et) Püridiini uued derivaadid ja neid sisaldavad ravimkoostised
EE05004B1 (et) Aminotiasooli derivaadid, nende valmistamine ja neid sisaldavad farmatseutilised kompositsioonid
DK1049706T3 (da) Hidtil ukendte pentasaccharider, fremgangsmåder til deres fremstilling og farmaceutiske præparater, der indeholder dem
EE05192B1 (et) Trptamiini derivaadid ja analoogsed hendid ning neid sisaldavad farmatseutilised preparaadid
EE9900435A (et) Püridiini uued derivaadid ja neid sisaldavad ravimkoostised
EE05274B1 (et) Androgeensed 7-asendatud 11-halogenosteroidid ja neid sisaldavad farmatseutilised kompositsioonid
EE200300161A (et) Triasooliderivaadid ja neid sisaldavad farmatseutilised kompositsioonid
EE200100592A (et) 14ß-H-steroolid, neid sisaldavad farmatseutilisedkompositsioonid ja nende derivaatide kasutamine meioosi reguleerivate ravimite valmistamiseks
EE200100474A (et) Antratsükliinide L-arabinodisahhariidid, nende valmistamise meetodid ning neid sisaldavad ravimkoostised

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231